The results indicated that SSPN, CD52, VPREB3, and CCDC82 were independent prognostic biomarkers, and the four-gene or five-gene signature could be developed as a promising prognostic biomarker panel for human DLBCL (Figure 4C). The gene discussed is CD52; the disease is diffuse large B-cell lymphoma.